Cytek Biosciences (CTKB) Deferred Taxes (2024 - 2026)

Cytek Biosciences has reported Deferred Taxes for 3 years, with the latest figure at -$183000.0 in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 45.54% year-over-year to -$183000.0; the trailing twelve-month figure through Mar 2026 stood at $33.7 million (up 1146.24% YoY), and the FY2025 full-year result was $33.6 million, up 1262.75% from the prior year.
• Deferred Taxes for Q1 2026 stood at -$183000.0, down from $38.6 million in the prior quarter.
• The five-year high for Deferred Taxes was $38.6 million in Q4 2025, with the low at -$2.9 million in Q4 2024.
• Historically, Deferred Taxes has averaged $5.1 million across 3 years, with a median of -$1.2 million in 2025.
• Annual changes were most pronounced in 2025 — Deferred Taxes surged 1436.66% — and 2026, when it surged 45.54%.
• Cytek Biosciences' Deferred Taxes stood at -$2.9 million in 2024, then surged by 1436.66% to $38.6 million in 2025, then sank by 100.47% to -$183000.0 in 2026.
• The last three Deferred Taxes figures came in at -$183000.0 (Q1 2026), $38.6 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.